Cargando…
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from preclinical in vitro and animal studies demonstrated its selectivity and efficacy. The phase I LOTIS-1 study for relapsed, ref...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943462/ https://www.ncbi.nlm.nih.gov/pubmed/35340719 http://dx.doi.org/10.1177/20406207221087511 |